Radiotherapy for asymptomatic brain metastasis in epidermal growth factor receptor mutant non-small cell lung cancer without prior tyrosine kinase inhibitors treatment: a retrospective clinical study

[1]  G. Bootsma,et al.  Patient selection for whole brain radiotherapy (WBRT) in a large lung cancer cohort: Impact of a new Dutch guideline on brain metastases , 2014, Acta oncologica.

[2]  Andreas Rimner,et al.  Erlotinib versus radiation therapy for brain metastases in patients with EGFR-mutant lung adenocarcinoma. , 2014, International journal of radiation oncology, biology, physics.

[3]  Mahmoud M El Gantery,et al.  Management of brain metastases with stereotactic radiosurgery alone versus whole brain irradiation alone versus both , 2014, Radiation oncology.

[4]  J. Shao,et al.  High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR , 2013, Journal of Translational Medicine.

[5]  J. Shao,et al.  High EGFR copy number predicts benefits from tyrosine kinase inhibitor treatment for non-small cell lung cancer patients with wild-type EGFR , 2013, Journal of Translational Medicine.

[6]  L. Ting,et al.  EGFR mutations are associated with favorable intracranial response and progression-free survival following brain irradiation in non-small cell lung cancer patients with brain metastases , 2012, Radiation oncology.

[7]  Dae-Ho Lee,et al.  Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation. , 2012, Lung Cancer.

[8]  Takashi Ogura,et al.  Metastatic brain tumors from non-small cell lung cancer with EGFR mutations: distinguishing influence of exon 19 deletion on radiographic features. , 2012, Lung cancer.

[9]  F. Kousar,et al.  Quality of life and symptoms control in brain metastasis after palliative whole brain radiotherapy using two different protocols. , 2012, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[10]  Z. Li,et al.  The retrospective analysis of the frequency of EGFR mutations and the efficacy of gefitinib in NSCLC patients with brain metastasis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  L. Sequist,et al.  EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. , 2010, Neuro-oncology.

[12]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[13]  T. Mok,et al.  Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis , 2009, Journal of cellular and molecular medicine.

[14]  Sang-We Kim,et al.  Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis. , 2009, Lung cancer.

[15]  J. Shih,et al.  Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  E. Stathopoulos,et al.  Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC , 2008, British Journal of Cancer.

[17]  Yih-Leong Chang,et al.  Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical Response , 2008, Clinical Cancer Research.

[18]  Tongtong Zhang,et al.  Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain. , 2007, Lung cancer.

[19]  T. Mok,et al.  Epidermal Growth Factor Receptor Mutations and Their Correlation with Gefitinib Therapy in Patients with Non-small Cell Lung Cancer: A Meta-Analysis Based on Updated Individual Patient Data from Six Medical Centers in Mainland China , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  J. Yokota,et al.  Frequent EGFR mutations in brain metastases of lung adenocarcinoma , 2006, International journal of cancer.

[21]  P. Brown,et al.  Whole-brain radiotherapy in the management of brain metastasis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Mehta,et al.  Current management of brain metastases, with a focus on systemic options. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Kris,et al.  High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib , 2005, Cancer.

[24]  Shih-Feng Tsai,et al.  High Frequency of Epidermal Growth Factor Receptor Mutations with Complex Patterns in Non–Small Cell Lung Cancers Related to Gefitinib Responsiveness in Taiwan , 2004, Clinical Cancer Research.

[25]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[26]  F. Cappuzzo,et al.  Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). , 2003, Lung cancer.

[27]  Allan H Friedman,et al.  Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[28]  Y Maruyama,et al.  A randomized trial of surgery in the treatment of single metastases to the brain. , 1990, The New England journal of medicine.

[29]  L. Collette,et al.  A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  H. Minn,et al.  Prognosis of patients treated for intracranial metastases with whole-brain irradiation. , 1998, Annals of medicine.